A detailed history of Transatlantique Private Wealth LLC transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Transatlantique Private Wealth LLC holds 3,515 shares of BMRN stock, worth $234,204. This represents 0.1% of its overall portfolio holdings.

Number of Shares
3,515
Previous 3,387 3.78%
Holding current value
$234,204
Previous $278,000 11.15%
% of portfolio
0.1%
Previous 0.11%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$69.02 - $93.84 $8,834 - $12,011
128 Added 3.78%
3,515 $247,000
Q2 2024

Aug 13, 2024

SELL
$74.43 - $92.22 $2,679 - $3,319
-36 Reduced 1.05%
3,387 $278,000
Q1 2024

May 13, 2024

SELL
$83.81 - $99.0 $2,849 - $3,366
-34 Reduced 0.98%
3,423 $298,000
Q4 2023

Feb 12, 2024

SELL
$76.22 - $98.51 $136,128 - $175,938
-1,786 Reduced 34.06%
3,457 $333,000
Q3 2023

Jun 25, 2024

BUY
$85.07 - $94.48 $154,827 - $171,953
1,820 Added 53.17%
5,243 $463,000
Q3 2023

Nov 13, 2023

SELL
$85.07 - $94.48 $4,423 - $4,912
-52 Reduced 0.98%
5,243 $464,000
Q2 2023

Jun 25, 2024

BUY
$86.68 - $100.3 $9,101 - $10,531
105 Added 2.02%
5,295 $458,000
Q2 2023

Aug 10, 2023

BUY
$86.68 - $100.3 $9,101 - $10,531
105 Added 2.02%
5,295 $459,000
Q1 2023

Jun 25, 2024

BUY
$87.74 - $117.27 $155,036 - $207,216
1,767 Added 51.62%
5,190 $504,000
Q1 2023

May 05, 2023

BUY
$87.74 - $117.27 $58,961 - $78,805
672 Added 14.87%
5,190 $505,000
Q4 2022

Jun 25, 2024

BUY
$80.93 - $108.63 $88,618 - $118,949
1,095 Added 31.99%
4,518 $467,000
Q4 2022

Feb 06, 2023

SELL
$80.93 - $108.63 $14,567 - $19,553
-180 Reduced 3.83%
4,518 $466,000
Q3 2022

Nov 04, 2022

BUY
$82.16 - $96.94 $4,108 - $4,847
50 Added 1.08%
4,698 $399,000
Q2 2022

Aug 01, 2022

BUY
$71.48 - $86.85 $332,239 - $403,678
4,648 New
4,648 $385,000

Others Institutions Holding BMRN

About BIOMARIN PHARMACEUTICAL INC


  • Ticker BMRN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,824,000
  • Market Cap $12.4B
  • Description
  • BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...
More about BMRN
Track This Portfolio

Track Transatlantique Private Wealth LLC Portfolio

Follow Transatlantique Private Wealth LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Transatlantique Private Wealth LLC, based on Form 13F filings with the SEC.

News

Stay updated on Transatlantique Private Wealth LLC with notifications on news.